News

Key news

EVENT

(Meet OncoDNA @ Carrefour de Pathologie - 4-7 Nov. Paris)

Posted on Oct. 21, 2019Read more

SCIENTIFIC

(International Alliance for Cancer Early Detection)

Posted on Nov. 12, 2019Read more

SCIENTIFIC

(Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics)

Posted on Nov. 12, 2019Read more

SCIENTIFIC

(DCCC Danish circulating tumor DNA network (DCCC ctDNA))

Posted on Nov. 12, 2019Read more

All news

- International Alliance for Cancer Early Detection
- Nov. 12, 2019
- read more
- Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
- Nov. 12, 2019
- read more
- DCCC Danish circulating tumor DNA network (DCCC ctDNA)
- Nov. 12, 2019
- read more
- FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer
- Nov. 12, 2019
- read more
- Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program
- Nov. 12, 2019
- read more
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- Nov. 12, 2019
- read more
- Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
- Nov. 12, 2019
- read more
- The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
- Nov. 12, 2019
- read more
- Multidimensional imaging provides evidence for down-regulation of T cell effector function by MDSC in human cancer tissue
- Nov. 4, 2019
- read more
- Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
- Nov. 4, 2019
- read more
- Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
- Nov. 4, 2019
- read more
- Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
- Nov. 4, 2019
- read more
- Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
- Nov. 4, 2019
- read more
- Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses
- Nov. 4, 2019
- read more
- Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection
- Nov. 4, 2019
- read more
- Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- Oct. 28, 2019
- read more
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- Oct. 28, 2019
- read more
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal AdenocarcinomaA Phase 2 Randomized Clinical Trial
- Oct. 28, 2019
- read more
- Meet OncoDNA @ Carrefour de Pathologie - 4-7 Nov. Paris
- Oct. 21, 2019
- read more
- Three early stage clinical trials have suggested benefit of adding checkpoint inhibition to BRAF ± MEK inhibitor therapy for patients with advanced BRAF-mutant disease.
- Oct. 21, 2019
- read more
- A trial looking at avelumab and chemotherapy for bowel cancer (POLEM)
- Oct. 21, 2019
- read more
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Oct. 21, 2019
- read more
- New Studies Question Whether Novel Anti-Cancer Drugs Are Worth Their Extra Cost
- Oct. 14, 2019
- read more
- LOXO-292 Demonstrates Promising Anti-Tumour Activity in RET-Altered Thyroid Cancer
- Oct. 14, 2019
- read more
- A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer
- Oct. 14, 2019
- read more
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- Oct. 14, 2019
- read more
- Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
- Oct. 14, 2019
- read more
- Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
- Oct. 14, 2019
- read more
- Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
- Oct. 14, 2019
- read more
- ESMO 2019 ratifies the need to implement genomic analysis in cancer treatment
- Oct. 10, 2019
- read more
- Breast Cancer: inactivating NF1 mutations are enriched in advanced BC and contribute to endocrine therapy resistance
- Oct. 7, 2019
- read more
- Drug targets. - Not all BRAF mutations are equal, falling into 3 different classes based on mechanism of action and therapeutic sensitivity
- Oct. 4, 2019
- read more
- Breast cancer. -Retrospective data suggest a role for mammography screening for high risk males
- Oct. 4, 2019
- read more
- Prostate cancer. -Amplification of the androgen receptor (AR) detected by ctDNA analysis is associated with poor response to anti-androgen therapy
- Oct. 4, 2019
- read more
- Lung Cancer: 3 key news from ESMO on atezolizumab (aPD-L1), Osimertinib 7 months extra survival, conflicting view on TMB
- Oct. 4, 2019
- read more
- Cholangiocarcinoma. - One third of patients with FGFR2 rearrangements showed response to targeted anti-FGFR therapy (pemigatinib) in the second line (post-chemo) setting.
- Oct. 4, 2019
- read more
- Hepatocellular carcinoma. - Nivolumab shows marginal benefit over sorafenib in the first line setting
- Oct. 4, 2019
- read more
- Ovarian cancer: 3 randomised controlled phase III clinical trials presented at ESMO establish the benefit of PARP inhibition ...
- Oct. 3, 2019
- read more
- Initiative solidaire : Signature d’un partenariat entre une société spécialisée en médecine de précision dans le cancer et un spécialiste du financement participatif
- Sept. 19, 2019
- read more
- OncoDNA’s Precision Medicine Solutions Available from Two Major Healthcare Providers in the UK
- Sept. 19, 2019
- read more
- OncoDNA and MD Anderson Cancer Center Madrid sign important collaboration agreement
- Sept. 19, 2019
- read more
- OVARIAN CANCER: Maintenance therapy with the PARP inhibitor niraparib improved progression free survival; it also increased the amount of time patients were without symptoms.
- Sept. 16, 2019
- read more
- The FDA have issued a warning of rare but potentially severe lung inflammation associated with CDK4/6 inhibitor therapy (palbociclib, ibociclib, abemaciclib).
- Sept. 13, 2019
- read more
- OncoDNA, a pioneering study demonstrates an impact of molecular profiling on the evolution of cancer
- Aug. 20, 2019
- read more
- The European Medicines Agency has followed the FDA's lead by granting tissue agnostic approval to the NTRK inhibitor larotrectinib for patients with NTRK-fusion cancers.
- Aug. 5, 2019
- read more
- OncoDNA adds the analysis of germinal DNA, a crucial marker in the management of ovarian, prostate, pancreas and triple-negative breast cancers
- July 29, 2019
- read more
- Findings from a new analysis of the large Prospective Lynch Syndrome Database
- July 27, 2019
- read more
- OncoDNA adds the analysis of germinal DNA, a crucial marker in the management of ovarian, prostate, pancreas and triple-negative breast cancers
- June 30, 2019
- read more
- OncoDNA, the central laboratory in the AURORA metastatic breast cancer research programme
- June 27, 2019
- read more
- OncoDNA launches a unique innovative RNA-based NTRK gene fusion molecular profiling solution
- Feb. 5, 2019
- read more
- Publication in El Economista: one of the world most read Spanish language newspaper
- Dec. 3, 2018
- read more
- OncoDNA announces ISO 27001 certification for information security management and storage
- Nov. 26, 2018
- read more
- OncoDNA: Winner of the Healthcare and Life Science category of Deloitte’s 2018 Technology Fast 50 competition.
- Nov. 16, 2018
- read more
- A first in Belgium: A mutuality involved in funding molecular diagnostic tests for cancer
- Nov. 13, 2018
- read more
- Première en Belgique : Intervention d’une mutualité dans le financement des tests de diagnostic moléculaire du cancer.
- Nov. 13, 2018
- read more
- OncoDNA is pleased to announce collaboration in the MDLUX2 program from INC (National Cancer Institute), Molecular Diagnostics Program funded by IBBL (Integrated BioBank of Luxembourg), the Fondation Cancer and the Fondatioun Kriibskr
- Oct. 29, 2018
- read more
- OncoDNA annonce collaborer au lancement de MDLUX2 par l’INC (Institut National du Cancer), programme de diagnostic moléculaire financé par la Fondation Cancer, la Fondatioun Kriibskrank Kanner et IBBL (Integrated BioBank of Luxembourg
- Oct. 29, 2018
- read more
- OncoDNA Signs Distribution Agreement with Gammaray Private Health Services in Turkey and AMS 2000 Trading Impex in Romania
- Oct. 21, 2018
- read more
- OncoDNA announces presentations of clinical study data at ESMO 2018 and new solid tumor analysis product release
- Oct. 17, 2018
- read more
- OncoDNA to provide diagnostics services to the world-class IMC hospital in Saudi Arabia
- Oct. 8, 2018
- read more
- OncoDNA included in Spanish medical oncology guidelines for diagnosis cancers of unknown primary origin
- Oct. 1, 2018
- read more
- OncoDNA expands international cancer precision medicine project Moncodaneum
- June 26, 2018
- read more
- OncoDNA announces screening collaboration with Kura Oncology
- May 22, 2018
- read more
- OncoDNA signs collaboration with BioClin Therapeutics for precision enrolment of lead drug Phase II clinical trial
- May 15, 2018
- read more
- OncoDNA announces uptake of reimbursement for key products among leading UK insurers
- May 9, 2018
- read more
- OncoDNA expands Executive Committee with Michelle Meijer as Sales & Marketing Director
- April 23, 2018
- read more
- OncoDNA announces publication of peer-reviewed study in Oncotarget assessing the utility of its unique biomarker analysis and interpretation platform in clinical decision making
- April 17, 2018
- read more
- Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor
- April 3, 2018
- read more
- PromTest LLC will market and distribute OncoDNA’s solutions to oncologists and cancer patients in Armenia
- March 27, 2018
- read more
- OncoDNA and NM Genomix Sign Distribution Agreement for Bulgaria
- Feb. 15, 2018
- read more
- SPHENE team is shortlisted for CANCER RESEARCH UK'S GRAND CHALLENGE
- Feb. 9, 2018
- read more
- OncoDNA reinforces its presence in the United Kingdom by appointing a Medical Director, Dr Philip Beer
- Jan. 10, 2018
- read more
- OncoDNA has inked a distribution agreement with GENEXT LLC (Russia)
- Jan. 29, 2017
- read more

Do you want to share some fresh news with us?

If you have something to say or something to share via our platform, feel free to contact us!

I have a topic to share

READ OUR FRESH

News

Key news

EVENT

(Meet OncoDNA @ Carrefour de Pathologie - 4-7 Nov. Paris)

Posted on Oct. 21, 2019Read more

SCIENTIFIC

(International Alliance for Cancer Early Detection)

Posted on Nov. 12, 2019Read more

SCIENTIFIC

(Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics)

Posted on Nov. 12, 2019Read more

SCIENTIFIC

(DCCC Danish circulating tumor DNA network (DCCC ctDNA))

Posted on Nov. 12, 2019Read more

All news

Do you want to share some fresh news with us?